Aclidinium bromide for the treatment of chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine

Volumn 6, Issue 6, 2012, Pages 581-588

  Gupta, Vandana ^a   Singh, Dave ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

aclidinium bromide; anticholinergics; bronchodilator; chronic obstructive pulmonary disease; lung function

Indexed keywords

ACLIDINIUM BROMIDE; FORMOTEROL; PLACEBO; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG METABOLISM; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84870978692     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.12.61     Document Type: Review

References (49)

1. Chapman KR, Mannino DM, Soriano JB et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 27(1), 188-207 (2006). (Pubitemid 43092683)
2. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 370(9589), 786-796 (2007). (Pubitemid 47320802)
3. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc. Am. Thorac. Soc. 4(7), 526-534 (2007). (Pubitemid 47547847)
4. Tashkin DP, Celli B, Senn S et al.; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359(15), 1543-1554 (2008).
5. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50(2), 279-290 (1998).
6. van Koppen CJ, Blankesteijn WM, Klaassen AB, Rodrigues de Miranda JF, Beld AJ, van Ginneken CA. Autoradiographic visualization of muscarinic receptors in pulmonary nerves and ganglia. Neurosci. Lett. 83(3), 237-240 (1987). (Pubitemid 18001457)
7. Barnes PJ. Muscarinic receptor subtypes in airways. Eur. Respir. J. 6(3), 328-331 (1993). (Pubitemid 23114874)
8. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2(4), 297-304; discussion 311 (2005). (Pubitemid 41566939)
9. Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 6(5), 404-415 (2009).
10. Brodde OE, Bruck H, Leineweber K, Seyfarth T. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res. Cardiol. 96(6), 528-538 (2001). (Pubitemid 33121025)
11. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br. J. Pharmacol. 148(5), 565-578 (2006). (Pubitemid 43993048)
12. Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic bronchodilators. Am. Rev. Respir. Dis. 129(5), 856-870 (1984). (Pubitemid 14104773)
13. Rogers DF. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr. Opin. Pharmacol. 2(3), 249-255 (2002). (Pubitemid 34594363)
14. Wessler IK, Kirkpatrick CJ. Activation of muscarinic receptors by non-neuronal acetylcholine. Handb. Exp. Pharmacol. 208, 469-491 (2012).
15. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Res. 7, 73 (2006).
16. Gross NJ. Ipratropium bromide. N. Engl. J. Med. 319(8), 486-494 (1988).
17. Barnes PJ, Belvisi MG, Mak JC, Haddad EB, O'Connor B. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci. 56(11-12), 853-859 (1995).
18. Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL, Hammer R. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 52(5-6), 537-544 (1993).
19. Littner MR, Ilowite JS, Tashkin DP et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161(4 Pt 1), 1136-1142 (2000). (Pubitemid 30243820)
20. Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat. Respir. Med. 3(4), 247-268 (2004). (Pubitemid 39263973)
21. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19(2), 217-224 (2002). (Pubitemid 34162820)
22. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300(12), 1439-1450 (2008).
23. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 342, d3215 (2011).
24. Aaron SD, Vandemheen KL, Fergusson D et al.; Canadian Thoracic Society/ Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 146(8), 545-555 (2007). (Pubitemid 351650535)
25. Prat M, Fernández D, Buil MA et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl] oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide (aclidinium bromide). J. Med. Chem. 52(16), 5076-5092 (2009).
26. Gavaldà A, Miralpeix M, Ramos I et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J. Pharmacol. Exp. Ther. 331(2), 740-751 (2009).
27. Sentellas S, Ramos I, Albertí J et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur. J. Pharm. Sci. 39(5), 283-290 (2010).
28. Albertí J, Martinet A, Sentellas S, Salvà M. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab. Dispos. 38(7), 1202-1210 (2010).
29. Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration 78(3), 322-328 (2009).
30. Magnussen H, Watz H, Zimmermann I et al. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir. Med. 103(12), 1832-1837 (2009).
31. Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int. J. Clin. Pharmacol. Ther. 47(7), 460-468 (2009).
32. Ortiz S, Flach S, Caracta C, Gil EG, Jansat JM. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants. J. Clin. Pharmacol. 52(6), 819-827 (2012).
33. 14C]-aclidinium bromide in healthy subjects. Biopharm. Drug Dispos. 33(1), 39-45 (2012).
34. Joos GF, Schelfhout VJ, Pauwels RA et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir. Med. 104(6), 865-872 (2010).
35. Chanez P, Burge PS, Dahl R et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm. Pharmacol. Ther. 23(1), 15-21 (2010).
36. Jones PW, Rennard SI, Agusti A et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir. Res. 12, 55 (2011).
37. Cazzola M, MacNee W, Martinez FJ et al.; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 31(2), 416-469 (2008).
38. Fuhr R, Magnussen H, Sarem K et al. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate-to-severe COPD. Chest 141(3), 745-752 (2012).
39. Singh D, Magnussen H, Kirsten A et al. A randomised, placebo-and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm. Pharmacol. Ther. 25(3), 248-253 (2012).
40. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 9(2), 90-101 (2012).
41. Jones PW, Singh D, Bateman ED et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 40(4), 830-836 (2012).
42. Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD 7(5), 331-336 (2010).
43. Maltais F, Celli B, Casaburi R et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate-to-severe COPD. Respir. Med. 105(4), 580-587 (2011).
44. O'Donnell DE, Flüge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 23(6), 832-840 (2004). (Pubitemid 38807355)
45. Stephenson A, Seitz D, Bell CM et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch. Intern. Med. 171(10), 914-920 (2011).
46. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir. Med. 101(7), 1398-1405 (2007). (Pubitemid 46832237)
47. D'Urzo A, Ferguson GT, van Noord JA et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res. 12, 156 (2011).
48. Hanania NA, Feldman G, Zachgo W et al. The efficacy and safety of the novel long-acting b2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 142(1), 119-127 (2012).
49. van Noord JA, Buhl R, Laforce C et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 65(12), 1086-1091 (2010).